First Time Loading...

AVITA Medical Inc
NASDAQ:RCEL

Watchlist Manager
AVITA Medical Inc Logo
AVITA Medical Inc
NASDAQ:RCEL
Watchlist
Price: 8.9 USD 1.71% Market Closed
Updated: May 7, 2024
Section:
 

Wall Street
Price Targets

RCEL Price Targets Summary
AVITA Medical Inc

Wall Street analysts forecast RCEL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RCEL is 26.32 USD with a low forecast of 21.21 USD and a high forecast of 42 USD.

RCEL Lowest Forecast
Wall Street Target
21.21 USD
138% Upside
RCEL Average Forecast
Wall Street Target
26.32 USD
196% Upside
RCEL Highest Forecast
Wall Street Target
42 USD
372% Upside
Lowest
Price Target
21.21 USD
138% Upside
Average
Price Target
26.32 USD
196% Upside
Highest
Price Target
42 USD
372% Upside
AVITA Medical Inc Competitors:
Price Targets
688366
Shanghai Haohai Biological Technology Co Ltd
35% Upside
RNA
Avidity Biosciences Inc
81% Upside
TRDA
Entrada Therapeutics Inc
59% Upside
GLPG
Galapagos NV
54% Upside
688366
Shanghai Haohai Biological Technology Co Ltd
35% Upside
RNA
Avidity Biosciences Inc
81% Upside
TRDA
Entrada Therapeutics Inc
59% Upside
GLPG
Galapagos NV
54% Upside
PHIL
Philogen SpA
31% Upside
300841
Chengdu Kanghua Biological Products Co Ltd
27% Upside
RYTM
Rhythm Pharmaceuticals Inc
37% Upside
1167
Jacobio Pharmaceuticals Group Co Ltd
188% Upside

Revenue
Forecast

Revenue Estimate
AVITA Medical Inc

For the last 1 year the compound annual growth rate for AVITA Medical Inc's revenue is 46%. The projected CAGR for the next 3 years is 43%.

46%
Past Growth
43%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
AVITA Medical Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
AVITA Medical Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
RCEL intrinsic value, competitors valuation, and company profile.
DCF Valuation
RCEL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RCEL stock valuation using valuation multiples.
Wall Street Estimates
RCEL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RCEL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RCEL's stock price target?
Price Target
26.32 USD

According to Wall Street analysts, the average 1-year price target for RCEL is 26.32 USD with a low forecast of 21.21 USD and a high forecast of 42 USD.

What is AVITA Medical Inc's Revenue forecast?
Projected CAGR
43%

For the last 1 year the compound annual growth rate for AVITA Medical Inc's revenue is 46%. The projected CAGR for the next 3 years is 43%.

ALPHA SPREAD
Join more than 134,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.